Cancer Drug Developer Nanobiotix Denies Any Active Takeover Process

Nanobiotix S.A. (NASDAQ:NBTX) shares are up on Wednesday as the company responds to recent media speculation regarding potential acquisition intentions. The stock's movement follows a statement clarifying that there is no ongoing process or assessment for a takeover, which has helped to stabilize investor sentiment as broader markets are experiencing gains. Earlier on Wednesday, reports in the media outlet La Lettre indicated potential interest from Johnson & Johnson (NYSE:JNJ). NBTX Denies Takeover Talks Amid Reports In a recent statement, Nanobiotix emphasized that it has identified factual inaccuracies in media reports suggesting a potential acquisition. The company reassured investors that it is not pursuing any control changes and remains focused on its innovative therapeutic approaches in biotechnology. Additionally, Nanobiotix is a late-stage clinical biotechnology firm that aims to revolutionize cancer treatment through its proprietary nanotechnology. This focus on enhancing treatment outcomes for patients is critical as the company continues to develop its product candidates. In 2023, the companies inked a global licensing, co-development, and commercialization agreement for the investigational, potential first-in-class radioenhancer NBTXR3. In 2025, Johnson & Johnson amended the agreement safeguarding Nanobiotix's path to sustainable cash flow through significant potential milestone payments. The shift significantly reduces Nanobiotix's financial burden and allows the company to focus on advancing its clinical pipeline. Nanobiotix Technical Analysis Currently, the stock is trading 2.4% below its 20-day simple moving average (SMA) but is 18.5% above its 50-day SMA, demonstrating longer-term strength. Over the past 12 months, shares have skyrocketed by 774.83%, and they are currently positioned closer to their 52-week highs than lows. The RSI is at 47.95, which is considered neutral territory. Meanwhile, MACD is at 1.0828, below its signal line at 1.9719, indicating bearish pressure on the stock. The combination of neutral RSI and bearish MACD suggests mixed momentum. Key Resistance: $32.50 Key Support: $30.00 Nanobiotix Benzinga Edge Momentum Score 99.58 Below is the Benzinga Edge scorecard for Nanobiotix S.A. American Depositary Shares, highlighting its strengths and weaknesses compared to the broader market: Momentum: Bullish (Score: 99.58) — Stock is outperforming the broader market. The Verdict: Nanobiotix's Benzinga Edge signal reveals a momentum-driven story, indicating strong performance relative to the market. NBTX Price Action: Nanobiotix shares were up 6.17% at $31.07 at the time of publication on Wednesday, according to Benzinga Pro data.